アブストラクト | BACKGROUND: Oxytocin and its analogue carbetocin are uterotonics whose prophylactic use is recommended to prevent postpartum haemorrhage, which is one of the leading causes of maternal deaths worldwide. However, both drugs can cause specific adverse effects and haemodynamic challenges. AIM: The aim of this work was to exploratively examine reports of adverse drug events of both drugs and to establish a comparative haemodynamic profile. METHOD: Using data extracted from the World Health Organization's pharmacovigilance database VigiBase, a descriptive analysis was performed of all reports for oxytocin and carbetocin as a suspected or interacting drug followed by a disproportionality analysis for haemodynamic events. Reporting odds ratios (ROR) of carbetocin for hypertension, hypotension, tachycardia, and bradycardia were calculated, with oxytocin-related reports serving as comparators. RESULTS: Oxytocin and carbetocin were mentioned as suspected or interacting drugs in 11,258 and 374 reports, respectively. Resulting RORs for carbetocin were 3.45 (95%CI: 1.72-6.92) for hypertension, 2.65 (1.64-4.28) for hypotension, 2.84 (1.79-4.49) for tachycardia, and 2.00 (0.87-4.60) for bradycardia, when compared to oxytocin. Of 231 patients for whom oxytocin-related tachycardia was reported, 2.6% died, and of 91 patients for whom bradycardia was reported, 2.2% died. No deaths were reported with carbetocin for any of the haemodynamic adverse events. CONCLUSION: Compared to oxytocin, carbetocin showed an elevated reporting for adverse hypertension, hypotension, and tachycardia in pharmacovigilance data. Clinicians should be aware of their patients' individual susceptibility and the possibility of haemodynamic deterioration until causal inferences are possible. |
ジャーナル名 | International journal of clinical pharmacy |
Pubmed追加日 | 2023/5/10 |
投稿者 | Stampfli, Dominik; Dommrich, Rebecca; Orbach-Zinger, Sharon; Burden, Andrea M; Heesen, Michael |
組織名 | Pharmacoepidemiology, Institute of Pharmaceutical Sciences, Department of;Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093,;Zurich, Switzerland. dominik.staempfli@pharma.ethz.ch.;Hospital Pharmacy, Kantonsspital Baden, Baden, Switzerland.;dominik.staempfli@pharma.ethz.ch.;Zurich, Switzerland.;Department of Anesthesia, Beilinson Hospital, Rabin Medical Center Associated;With Sakler Medical School, Tel Aviv University, Tel Aviv, Israel.;Department of Anaesthesia, Kantonsspital Baden, Baden, Switzerland. |
Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37162656/ |